UBS Upgrades Hospira (HSP) to Neutral

UBS upgraded Hospira (NYSE: HSP) from Sell to Neutral.

The firm comments, "We are updating our model to reflect the recent FDA import restriction on US devices and the 483 letter at Rocky Mt. which lowered our 2013 and 2014 EPS to $2.05 (cons. $2.05) and $2.15 (cons. $2.09), resp. We do not see sig. downside from here as we believe that consensus has already factored in the negative news and while there is still potential risk of a Consent Decree it may not result in a sig. incremental headwind to earnings unless FDA decides to levy fines on Hospira."

For an analyst ratings summary and ratings history on Hospira click here. For more ratings news on Hospira click here.

Shares of Hospira closed at $29.66 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• INVO Fertility (IVF) Tops Q2 EPS by 105c